Learning from both success and failure in severe asthma
The NIHR’s Professor Chris Brightling explains how negative results from an asthma study can teach us just as much as positive results
Read More
Search Results for: Professor Chris Brightling
New asthma pill to target airway muscles
Researchers are developing a new asthma pill Fevipiprant to target airway muscles to decrease attacks, potentially offering the first new oral treatment for asthma in 20 years.
Read More
UK study to research long-term health impact of COVID-19
The PHOSP-COVID study will support the development of new strategies for clinical and rehabilitation care
Read More
Novartis’ fevipiprant hailed a “game-changer” in asthma treatment
Researchers are hailing Novartis’ fevipiprant (QAW039) as a game-changer in asthma treatment after a Lancet-published trial showed its potential to significantly reduce the severity of the condition.
Read More- Cambridge researchers develop robotic nerve devices for neurological conditions
- International phase 3 clinical trial for new melanoma treatment recruits first patients
- Nova’s Xromi approved in UK and EU for vaso-occlusive complications of SCD
- Study reveals vitamin D-altered mouse gut bacteria provides better cancer immunity
- Cambridge researchers use AI to accelerate drug design for Parkinson’s disease
